Steven J. Lemery

United States Food and Drug Administration

Also affiliated with Center for Drug Evaluation and Research

MedicineEconomics, Econometrics and Finance

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 14 papers. Top paper: “FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors”.

FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0459

N/A

2.2DataRank · unranked

84 citations

Diana Bradford, Michelle Marcovitz, Anup Amatya, Pallavi S. Mishra‐Kalyani, Emily Nguyen +17 more

FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2036

N/A

1.6DataRank · unranked

60 citations

Leigh Marcus, M. Naomi Horiba, Martha Donoghue, Somak Chatterjee, Pallavi S. Mishra‐Kalyani +12 more

FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-2124

N/A

1.4DataRank · unranked

64 citations

Jamie R. Brewer, Jiaxin Fan, Joyce Cheng, Yuan Li Shen, Yue Xiang +6 more

FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2 -Positive RAS Wild-Type Colorectal Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1041

N/A

1.1DataRank · unranked

38 citations

M. Naomi Horiba, Mengdie Yuan, Joyce Cheng, Steven J. Lemery, Yuan Li Shen +10 more

FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-4462

N/A

0.626DataRank · unranked

64 citations

Shan Pradhan, Lola A. Fashoyin‐Aje, Yi Ren, Yuan-Li Shen, Yuan Xu +12 more

FDA Approval Summary: Nivolumab for the Adjuvant Treatment of Adults with Completely Resected Esophageal/Gastroesophageal Junction Cancer and Residual Pathologic Disease

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-0617

N/A

0DataRank · unranked

10 citations

Sandra J. Casak, Pallavi S. Mishra‐Kalyani, Pourab Roy, Julia A. Beaver, Richard Pazdur +4 more

FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1042

N/A

0DataRank · unranked

21 citations

Sandra J. Casak, Sirisha L. Mushti, Joyce Cheng, Sriram Subramaniam, Hong Zhao +15 more

FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0281

N/A

0DataRank · unranked

25 citations

Sandra J. Casak, Sirisha L. Mushti, Joyce Cheng, Brian J. Christmas, Matthew D. Thompson +16 more

FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0327

N/A

0DataRank · unranked

580 citations

Lola A. Fashoyin‐Aje, Martha Donoghue, Mengdie Yuan, Lisa Rodríguez, Pamela Gallagher +7 more

FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0517

N/A

0DataRank · unranked

23 citations

Vaibhav Kumar, Chi Song, Mengdie Yuan, Anup Amatya, Joyce Cheng +9 more

FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0557

N/A

0DataRank · unranked

180 citations

Leigh Marcus, Lola A. Fashoyin‐Aje, Sirisha L. Mushti, Joyce Cheng, Yuan Li Shen +8 more

Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case Examples

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4912

N/A

0DataRank · unranked

29 citations

Mallorie H. Fiero, Erik Bloomquist, A. K. Sinha, Steven J. Lemery, Harpreet Singh +13 more

The FDA Oncology Center of Excellence Scientific Collaborative: Charting a Course for Applied Regulatory Science Research in Oncology

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4429

N/A

0DataRank · unranked

4 citations

Yutao Gong, Kirsten B. Goldberg, Paul G. Kluetz, Marc R. Theoret, Laleh Amiri‐Kordestani +13 more

FDA Approval Summary: Ripretinib for Advanced Gastrointestinal Stromal Tumor

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2400

N/A

0DataRank · unranked

12 citations

Leslie Doros, Margaret Thompson, Sirisha L. Mushti, Rosane Charlab, Elizabeth I. Spehalski +8 more